anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A novel process is provided for producing pramipexole base or its optical isomeric mixture as defined hereinabove i.e. (R,S)-2-amino-6-propyl-4,5,6,7-tetrahydrobenzothiazole avoiding the use of borane tetrahydrofuran complex and using a more convenient reducing agent like sodium triacetoxyborohydride instead. The provided process comprises reacting the starting material (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole or its optical isomeric mixture as defined hereinabove i.e. (R,S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with propionaldehyde in an organic solvent to obtain the respective enamine, which is subsequently reduced in situ, optionally without isolation, to obtain pramipexole or its optical isomeric mixture as defined hereinabove i.e. (R,S)-2-amino-6-propyl-4,5,6,7-tetrahydrobenzothiazole, and the acid addition salts thereof. The present invention also provides a process for purifying pramipexole dihydrochloride or the dihydrochloride salt of its optical isomeric mixture as defined hereinabove i.e. (R,S)-2-amino-6-propyl-4,5,6,7-tetrahydrobenzothiazole dihydrochloride by re-crystallization from a suitable solvent.
PURPOSE: A cosmetic composition containing enzyme and precursor with an activity at low temperature is provided to promoter skin cell activation and to improve anti-wrinkling and elasticity. CONSTITUTION: A cosmetic composition contains an enzyme with an activity at 0°C-15°C and at least one precursor which produces an active ingredient by reaction with the enzyme. The enzyme is hydrolase such as lipase, choline esterase, phosphatase, dioxyribonuclease, carboxypeptidase, pepsin, trypsin, or chemotrypsin. The precursor is retinyl palmitate, tocopheryl acetate, or piceid. The cosmetic composition is used for anti-aging, skin moisturizing, or skin whitening. The active ingredient is retinol, tocopherol, or resveratrol.
To assess the influence of prucalopride (Resolor®) 2mg daily, 30 patients with idiopathic and 30 patients with diabetic gastroparesis will undergo two gastric emptying breath tests with concomitant assessment of meal-related symptoms, at the conclusion of two consecutive, 4-week treatment periods of prucalopride or placebo. The order of prucalopride and placebo treatment will be randomised at the initiation of the study. Medication for both patient groups, 30 patients with idiopathic and 30 patients with diabetic gastroparesis, will be randomized separately. Half of the subjects will receive placebo first; the other half will receive prucalopride first. Treatment periods will be separated by a wash-out period of 2 weeks. All drugs potentially affecting gastrointestinal motility or sensitivity will be discontinued at least two weeks prior to the initiation of the study. Informed consent will be obtained from each participant.

In order to establish the gastrointestinal symptom and quality-of-life profile of this cohort, each patient will complete the following validated self-reported instruments at baseline and at each of the two testing visits (table 1): Patients assessment of Gastrointestinal symptoms (PAGISYM), Patients assessment of Gastrointestinal Quality of Life Impact (PAGIQoL) Gastrointestinal and Global Severity Score, Patient Health Questionnaire (PHQ-15), Appetite Questionnaire, Hospital Anxiety and Depression Scale, Visceral Sensitivity Index, Short Form Nepean Dyspepsia Index (SF-NDI). The PAGI-SYM is a comprehensive questionnaire of upper GI symptoms, and it includes a gastroparesis questionnaire module: the Gastroparesis Cardinal Symptom Index (GCSI), which has been validated in (idiopathic) gastroparesis.26 Furthermore, during the entire study duration patients will complete a daily symptom diary, incorporating a separate horizontal 100-mm visual analogue scale (VAS) for each of 9 upper abdominal symptoms. As prucalopride has a well-known therapeutic effect in chronic constipation, patients will also register information about their stool frequency and stool type in the daily diary (Bristol Stool Scale).
BACKGROUND: Whilst disease severity can significantly impact functional outcomes, the ability to predict the scale of this impact has not been consistent.
AIM: We aimed to investigate whether changes in disease severity within the first 48 h of ICU admission are more strongly associated with physical dysfunction than a single-time assessment of disease severity at ICU admission.
METHODS: A multicentre retrospective study in seven tertiary ICUs in Japan, including all consecutive adult ICU patients (>48 h ICU stay) between September 2019 and February 2020. The primary outcome was physical function defined as the Barthel Index, which is an ordinal scale (0-100: larger indicates better function) to measure physical independence and performance. The association between Barthel Index score at hospital discharge and the Sequential Organ Failure Assessment (SOFA) scores, measured at ICU admission, the highest recorded score within 48 h of ICU admission, and the level of change between these two timepoints were investigated in multivariable analysis.
RESULTS: A total of 199 patients were included. Median SOFA score at ICU admission and the highest recorded score within the first 48 h were 6 (interquartile range: 5-10) and 8 (interquartile range: 6-11), respectively. A quarter of patients had a Barthel Index score of 60 or less at hospital discharge. The highest SOFA score within 48 h of ICU admission and the level of change in SOFA scores between ICU admission and the highest recorded score within 48 h were significantly associated with lower Barthel Index scores at hospital discharge. No significant association was identified with regard to Barthel Index scores and SOFA score at ICU admission. An increase in SOFA score of 1 or more within the first 48 h of ICU admission was the threshold to predict a Barthel Index score of 60 or less at hospital discharge. Larger changes in SOFA scores over the first 48 h of ICU admission were also significantly associated with smaller changes in Barthel Index scores from ICU discharge to hospital discharge.
CONCLUSIONS: The level of change in SOFA score between ICU admission and the highest recorded score within the first 48 h of ICU stay can more accurately predict the presence of physical dysfunction at hospital discharge than a single-time assessment of disease severity at ICU admission. The larger worsening in SOFA potentially indicates lower recovery after a critical illness.
SUPPRELIN LA is a sterile, non-biodegradable, diffusion-controlled, hydrogel polymer reservoir containing histrelin acetate, a synthetic nonapeptide analog of the naturally occurring gonadotropin releasing hormone (GnRH) possessing a greater potency than the natural sequence hormone. SUPPRELIN LA is designed to deliver approximately 65 mcg histrelin acetate per day over 12 months.

The SUPPRELIN LA implant looks like a small thin flexible tube and consists of a 50-mg histrelin acetate drug core inside a 3.5 cm by 3 mm, cylindrical, hydrogel polymer reservoir (Figure 1). The implant may appear partially to completely full with variation in color from off-white to light brown. The color may be uneven within the core.

Figure 1. SUPPRELIN LA Implant Diagram (not to scale)

The chemical name of histrelin acetate is: L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-N-benzyl-D-histidyl-L-leucyl-L-arginyl-L-proline N-ethylamide, acetate salt. 

The molecular formula for histrelin acetate is C66H86N18O12 x 2 CH3COOH and its molecular weight is 1443.70 (or 1323.52 as free base). Histrelin is also chemically described as 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-Nt-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide diacetate. The chemical structure of the free base (histrelin) is represented below in Figure 2.

Figure 2. Structure of Histrelin

The drug core also contains the inactive ingredient stearic acid NF. The hydrogel polymer reservoir is a hydrophilic cartridge composed of 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, trimethylolpropane trimethacrylate, benzoin methyl ether, Perkadox-16, and Triton X-100. Each implant is packaged hydrated in a glass vial containing 2 mL of sterile 1.8% sodium chloride solution, so that it is primed for immediate release of the drug upon insertion.

A single use, sterile, Insertion Tool is provided along with the implant that can be used for the placement of the SUPPRELIN LA implant into the subcutaneous tissue of the inner aspect of the upper arm. The Insertion Tool is enclosed in a sterile bag and is provided separately from the implant in the Implantation Kit [see Recommended Procedure for Implant Insertion and Removal (2.2)].
This study is an investigation of the construct validity and user experience of a new delivery system for the General Anxiety Disorder - 7 (GAD 7), a clinically accepted tool for diagnosing general anxiety disorder. The purpose of the study is to examine if the new delivery system of the GAD 7 is effective at capturing participant anxiety levels and to assess the differences of usability between the paper and voice administered versions. The voice administered version uses a Mirror device, which is similar to a smart television with a mirror interface. The device records auditory responses to the GAD 7 through Amazon Alexa. The investigators will be comparing the responses on the new device to those given on the clinically established paper format. If proven effective at capturing depression levels of patients, future studies may investigate if the new format can be used to improve at home clinical care.
All subjects that meet initial study entry criteria will receive a test dose of 0.25mg of oral risperidone. Subjects who continue to be eligible will return to the clinical unit in one week and receive a single dose of 60mg RBP-7000 after a 2 hour fast. Subjects will remain in the clinical unit for 14 days, then return for 10 additional weeks after discharge.
Today, the consideration of the side effects of intensive treatment measures and their influence on quality of life are regarded as standard procedures in oncology. Quality of life measurements have found their way into clinical studies as patient-reported outcomes. In comparison to other tumor types, the field of dermato-oncology has had less research activity concerning quality of life. However, in recent years more attention has been paid to health related quality of life in malignant melanoma patients, especially under adjuvant treatment with interferon-alpha. Data about high dose IFN-α treatment, especially from the USA, show that there are significant physical and psychological side effects, such as fatigue and depression, which often lead to dosage reduction or termination of treatment. As yet, there are very few systematic studies about low dose IFN-α treatment, especially in regard to the side effects during the course of the disease.

Concerning treatment side-effects it is known throughout various areas of oncology that specific psycho-oncological interventions assist in the patients' adaptation to the illness and handling of the side effects of therapy.
They will be given breathing exercise training and will be asked to do it every day. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. There will be no interviews in the control group.
Ultrasound imaging will be taken from a group of subjects recruited for stage 2. These will be obtained through medical record review from subjects with successful renal transplant at BWH and no transplant rejection.
Nowadays, there is an increasing emphasis on the need to alleviate the chronic inflammatory response to effectively treat hypertension. However, there are still gaps in our understanding on how to achieve this. Therefore, research on interaction of antihypertensive drugs with the immune system is extremely interesting, since their therapeutic effect could partly result from amelioration of hypertension-related inflammation, in which macrophages seem to play a pivotal role. Thus, current comprehensive studies have investigated the impact of repeatedly administered hypotensive drugs (captopril, olmesartan, propranolol, carvedilol, amlodipine, verapamil) on macrophage functions in the innate and adaptive immunity, as well as if drug-induced effects are affected by a high-sodium diet (HSD), one of the key environmental risk factors of hypertension. Although the assayed medications increased the generation of reactive oxygen and nitrogen intermediates by macrophages from standard fed donors, they reversed HSD-induced enhancing effects on macrophage oxidative burst and secretion of pro-inflammatory cytokines. On the other hand, some drugs increased macrophage phagocytic activity and the expression of surface markers involved in antigen presentation, which translated into enhanced macrophage ability to activate B cells for antibody production. Moreover, the assayed medications augmented macrophage function and the effector phase of contact hypersensitivity reaction, but suppressed the sensitization phase of cell-mediated hypersensitivity under HSD conditions. Our current findings contribute to the recognition of mechanisms, by which excessive sodium intake affects macrophage immune activity in hypertensive individuals, and provide evidence that the assayed medications mitigate most of the HSD-induced adverse effects, suggesting their additional protective therapeutic activity.
The present invention provides a manufacturing process for quick dissolving products having active ingredients directed to agrochemical applications, such as plant applications and animal and animal health applications. Electrohydrodynamic (EHD) spraying is used to form a product form preferably comprised of fibers that contains a desired agrochemical compound formulated to quickly disintegrate on contact with a solvent such as water. The dispersed chemical is then provided as a sprayable solution. Because the product form contains little or no liquid, significant size and weight savings are gained, higher active ingredient loadings may be placed in a smaller amount of material, and manufacturing, packaging and transportation costs are thereby reduced without impacting user-friendliness. In addition, the EHD manufacturing method of the present invention also permits combining active ingredients previously not capable of effective use together in a single product. Small, low cost and potentially modular production operations may be used to practice the invention, thus enabling production facilities to be located close to markets, and product design specific to local or regional markets.
PROBLEM TO BE SOLVED: To obtain an O/W type emulsified composition, capable of reducing the particle size of an emulsion to an ultrafine one and excellent in especially emulsification stability with time by using a surfactant as an emulsifying agent and further an emulsion stabilizing assistant in combination. SOLUTION: This emulsified composition is obtained by using a surfactant as an emulsifying agent and further an alkyl glyceryl ether and cholesteryl N-acylglutamate as an emulsification stabilizing assistant in combination. Glycerol monostearyl ether, etc., are cited as the alkyl glyceryl ether and a compound, etc., of the formula (R<1> and R<2> are each cholesteryl, 2-octyldodecyl, etc.) are cited as the cholesteryl N-acylglutamate. Various surfactants can be selected as the surfactant according to the objective substance. The blending ratio thereof is preferably about 2-8wt.% based on the total amount of the composition. The blending ratio of the emulsification stabilizing assistant of the alkyl glyceryl ether:cholesteryl N-acylglutamate (expressed in terms of weight) is preferably 1:(0.5-10), especially preferably 1:(1-5).
Wellness estimation allows tracking of various health parameters and estimating health condition(s) of the user being monitored. Photophlethysmogram (PPG) based health monitoring systems exist. This disclosure relates generally to PPG based wellness monitoring, and more specifically to a pulse harmonics based wellness estimation. The system collects PPG signals from a user being monitored, as input. The system calculates 12 pulse harmonics from a fundamental frequency of the PPG signal. From the pulse harmonics, further a plurality of key features are extracted, and in turn a wellness metric and a wellness index are calculated, which represents health of the user.
Patients in this arm will undergo surgical resection of both the primary tumor and liver metastases. The surgical approach, extent of resection, and perioperative management will follow the standard protocols at each participating center. Venous vascular resections might be performed to reach radicality. Either standard or parenchyma sparing liver resections might be performed for resection of the liver metastases. Alternatively, needle ablation/microwave on the liver lesions is possible for lesions \<20 mm if technically feasible. Post-operative chemotherapy and/or radiotherapy could be administered as per multi-disciplinary decision based on case-by-case evaluation.
Methods for removing, reducing, dispersing, disrupting or eradicating biofilms present on a surface may include contacting the biofilm with a composition including an agent that reduces the potency of an aminopeptidase in the biofilm. The agent may reduce expression, secretion or extracellular activity of the aminopeptidase in the biofilm. The biofilm may be formed by  P. aeruginosa  or  P. stutzeri . The composition may enhance the sensitivity of  P. aeruginosa  to ciprofloxacin. Methods of determining the number of bacterial population in biofilm or a culture containing bacterial aggregate may include dispersing the bacterial aggregate or biofilm by using a composition comprising exogenous PslG. The number of bacteria may be determined based on the dispersed bacteria.
Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, integrated with the mobile health care environment (MHCE) system. The MHCE system will provide tailored behavioral messages triggered by clinical values and survey responses.
The present invention relates to a recombinant nucleic acid molecule for controlling mitochondrial activities using light stimulation and, more specifically, to a recombinant nucleic acid molecule in which a gene encoding ABCB10 protein and a gene encoding rhodopsin protein are linked to each other and a recombinant vector containing the same, a composition for controlling mitochondrial activities, or a method for controlling mitochondrial activities using light. In case of using the recombinant nucleic acid molecule according to the present invention, the recombinant nucleic acid molecule in which a gene encoding ABCB10 protein and a gene encoding rhodopsin protein are linked to each other is transfected into a cell. Thus, the function or activity of rhodopsin protein can be controlled by applying light stimulation. As a result, mitochondrial activities can be reversibly controlled by light stimulation with spatiotemporal precision. In addition, since light is used as a stimulus, light can be controlled with precise in various ranges by regulating the wavelength and intensity of a light source such as LED, laser, or the like. Moreover, as optic technology is developed, the advantages can be continually applied. Thus, the method is simple and has an excellent effect in controlling mitochondrial activities. Therefore, the roles of mitochondria with various functions such as a signal transduction process, energy production, and the like in each tissue can be deeply understood, so the present invention can be importantly applied to diagnose and study diseases related to mitochondrial activities.
Fatigue as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Systems and methods are disclosed for monitoring adherence to healthcare guidelines defining a recommended level of physical activity. Metabolic Equivalent (MET) data for a user over a plurality of days is analysed to determine whether sufficient MET data is available, by determining whether the obtained MET data includes at least a minimum amount of MET data within a defined time period. In response to a determination that sufficient MET data is available, the MET data is compared to guideline MET values relating to the recommended level of physical activity, to determine whether the user has achieved the recommended level of physical activity. An adherence result is outputted in accordance with the result of the comparison, indicating whether the user has achieved the recommended level of physical activity. The adherence result can be outputted in the form of a message displayed on a display unit. In some embodiments when MET data is captured over a plurality of days, it can be checked whether data has been captured for at least a minimum required number of days within a time period, for example one week.
Cytokine-mediated systemic inflammation after open thoracoabdominal aortic aneurysm (TAAA) repairs plays a pivotal role in disrupting circulatory homeostasis, potentially leading to organ dysfunction. The bioactive form of adrenomedullin (bio-ADM) is a peptide hormone with immunomodulatory and vasomotor effects, making it a potential diagnostic agent in these cases. This retrospective, bicentric study, conducted between January 2019 and December 2022, recruited 36 elective open TAAA repair patients in two German centres. Serum and plasma samples were collected at multiple time points to measure bio-ADM levels. The primary objective was to evaluate the association of bio-ADM levels with the onset of acute respiratory distress syndrome (ARDS), with secondary endpoints focusing on mortality and SIRS-related morbidity. Results showed a significant association between postoperative bio-ADM levels (12-48 h after surgery) and the onset of ARDS (p < .001), prolonged ventilation (p = .015 at 12h after surgery), atrial fibrillation (p < .001), and mortality (p = .05 at 24h). The biomarker was also strongly associated with sepsis (p = .01 at 12 h) and multi-organ dysfunction syndrome (MODS) (p = .02 at 24 h after surgery). The study underscores the potential utility of bio-ADM as a diagnostic tool for identifying patients at risk of postoperative complications following open TAAA repairs.
If withdrawal of bisoprolol fumarate and hydrochlorothiazide therapy is planned, it should be achieved gradually over a period of about 2 weeks. Patients should be carefully observed.

Patients with Renal or Hepatic Impairment: As noted in the WARNINGS section, caution must be used in dosing/titrating patients with hepatic impairment or renal dysfunction. Since there is no indication that hydrochlorothiazide is dialyzable, and limited data suggest that bisoprolol is not dialyzable, drug replacement is not necessary in patients undergoing dialysis. 

Geriatric Patients: Dosage adjustment on the basis of age is not usually necessary, unless there is also significant renal or hepatic dysfunction (see above and WARNINGS section). 

Pediatric Patients: There is no pediatric experience with bisoprolol fumarate and hydrochlorothiazide.